<?xml version="1.0" encoding="UTF-8"?>
<ref id="B50">
 <label>50.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Mulligan</surname>
    <given-names>MJ</given-names>
   </name>
   <name>
    <surname>Lyke</surname>
    <given-names>KE</given-names>
   </name>
   <name>
    <surname>Kitchin</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Absalon</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Gurtman</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Lockhart</surname>
    <given-names>SP</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report</article-title>. 
  <source>medRxiv [Preprint].</source> (
  <year>2020</year>). 
  <pub-id pub-id-type="doi">10.1101/2020.06.30.20142570</pub-id>
  <?supplied-pmid 32785213?>
  <pub-id pub-id-type="pmid">32785213</pub-id>
 </mixed-citation>
</ref>
